US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.
Kevin Kunzmann
Advertisement
Articles by Kevin Kunzmann
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
2
Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
3
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
4
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
5